Ophthalmic Drugs 2018
  • Copthorne Tara Hotel London Kensington, Scarsdale Place, Greater London, United Kingdom
    W8 5SY
  • Monday 26th November, 8:30am - Until Tuesday 27th November, 5:30pm
SMi's 2nd annual Ophthalmic Drugs conference returning to London, takes place at the Copthorne Tara Hotel in Kensington, on the 26th - 27th November 2018.

As the global population ages, the incidence of ophthalmic disorders continues to grow, and thus the interest of pharmaceutical and biotech companies is increasingly focused towards innovation of novel approaches for the development of ophthalmic drugs, driving the growth of the global ophthalmic drug market, which is projected to reach £30 billion by 2023.

Building on last year's success, this must-attend conference will bring together industry experts to discuss and analyse the latest advancements and challenges within ophthalmic drug development and delivery. Some notable areas of interest have been neuroprotection in ophthalmology, advancements in gene therapy, AMD clinical trial updates, and novel approaches for delivery of ocular drugs. The two-day event will also feature two interactive workshops on the 28th November 2018, led by twoXAR and Aston University

This Year's Agenda Highlights Include:

Discover recent advances in the treatment of glaucoma
Gain insight into the first FDA-approved gene therapy, developed for the treatment of inherited retinal dystrophy
Discuss case studies on novel non-invasive and site-specific drug delivery strategies
Examine the applications of artificial intelligence in drug discovery
Explore use of biomarkers and surrogate end-points from a regulatory perspective

Chairs for 2018:

Mitchell de long, Vice President, Chemistry, Aerie Pharmaceuticals
Naj Sharif, Executive Director and Head, Global Alliances and External Research, Santen

Key Speakers:

Majid Anderesi, Associate Group Clinical Director, Ophthalmology, Roche
Caroline Barelle, CEO, Elasmogen
Victor Chong, Global Head of Ophthalmology, Boehringer Ingelheim
Daniel Chung, Clinical Ophthalmic Lead, Spark Therapeutics
Aniz Girach, Chief Medical Officer, Nightstar Therapeutics
Peter Morgan-Warren, Medical Assessor, Licensing Division, MHRA
David Silverman, Clinical Director, Ophthalmology, Roche

View the full agenda: www.ophthalmicdrugs.com/evv 

Standard Price (Early Bird Rates Available Online): GBP 1499.0

Category: Conferences | Science, Health and Medicine | Ophthalmology

Social Interaction
* thebestof cannot be held responsible for any changes, amends or cancellations of an event